Skip to Main Content

Paper Details

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
Nat Med
132
2017
BET, BET protein, BETs, BRD2, BRD3, BRD4 proteins, CUL3, Cancer, SPOP, SPOP mutants, SPOP mutations, cancer, cancer cells, cancer driver gene, cancer-type, endometrial, endometrial and prostate cancers, endometrial cancer, patients, prostate cancer, ubiquitin, ubiquitin ligase
Author NameAffiliation
Gregory V KryukovBroad Institute of Harvard and MIT
Michael E CarneyJohn A. Burns School of Medicine, University of Hawaii at Manoa
Andrew BerchuckDuke Cancer Center
Boris WinterhoffUniversity of Minnesota
Holger MochInstitute of Surgical Pathology, University Hospital Zurich
Holger MochInstitute of Surgical Pathology, University Hospital Zurich
Matthias Peter
Steven A Carr
Steven A Carr
Levi A GarrawayBroad Institute of Harvard and MIT
Levi A GarrawayUniversity of Texas MD Anderson Cancer Center
Levi A GarrawayCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute
Levi A GarrawayBroad Institute of Harvard and MIT
Levi A GarrawayUniversity of Texas MD Anderson Cancer Center
Levi A GarrawayCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute
Peter J WildInstitute of Surgical Pathology, University Hospital Zurich
Jean-Philippe TheurillatInstitute of Oncology Research, Oncology Institute of Southern Switzerland
Jean-Philippe TheurillatUniversita della Svizzera Italiana
Jean-Philippe TheurillatCentre Hospitalier Universitaire Vaudois, University of Lausanne
  • 1 - 19

Datasets

Release 1.2